Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | HBB | P68871 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.41 |
| ▸ | POLG | P54098 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valacyclovir SCHEMBL34375 | 1.00 | KMT2A (0.72) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL29689659 | 0.99 | HBB (0.72) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL1888797 | 0.98 | KMT2A (0.69) | KMT2AMEN1HBBMAPK1PDE3A | |
| SCHEMBL23948433 | 0.86 | KMT2A (0.53) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL20570801 | 0.85 | MEN1 (0.75) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valganciclovir SCHEMBL336814 | 0.85 | PDE3A (0.78) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL4656778 | 0.84 | MEN1 (1.00) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL8444387 | 0.84 | MEN1 (1.00) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL13575743 | 0.84 | MEN1 (1.00) | KMT2AMEN1HBBMAPK1PDE3A | |
| Valacyclovir SCHEMBL28644 | 0.84 | MEN1 (1.00) | KMT2AMEN1HBBMAPK1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046715-A1 | Medicament for Treating Peripheral Neuropathies | HSIAO LILY (TW) | 2020-02-13 | — | — | US | claimed |
| US-10471064-B2 | Medicament for treating peripheral neuropathies | Hsiao, Lily (TW) | 2019-11-12 | — | — | US | claimed |
| US-20180193348-A1 | Medicament for Treating Peripheral Neuropathies | HSIAO LILY (TW) | 2018-07-12 | — | — | US | claimed |
| US-20170056408-A1 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES | YU HSIAO LILY (JP) | 2017-03-02 | — | — | US | claimed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | claimed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-9526729-B2 | Medicament for treating peripheral neuropathies | Yu, Hsiao Lily (JP) | 2016-12-27 | — | — | US | claimed |
| US-20150238493-A1 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES | YU HSIAO LILY (JP) | 2015-08-27 | — | — | US | claimed |
| US-20140213600-A1 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES | HSIAO LILY (TW) | 2014-07-31 | — | — | US | claimed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20220169705-A1 | TOPICAL APPLICATION FOR AN ANTI-HSV ANTIBODY | HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| CN-114306596-A | Topical application of anti-HSV antibodies | 海德堡免疫疗法有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11267871-B2 | Topical application for an anti-HSV antibody | Heiselberg ImmunoTherapeutics GmbH (DE) | 2022-03-08 | — | — | US | disclosed |
| CN-106488931-B | Topical application of anti-HSV antibodies | 海德堡免疫疗法有限公司 | 2021-12-28 | — | — | CN | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-7629461-B2 | Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2009-12-08 | — | — | US | disclosed |
| WO-2009129094-A2 | COMPOSITIONS CONTAINING ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | MALLINCKRODT INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | KMT2A 3346/4885MEN1 3203/4885HBB 3885/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | KMT2A 1703/4885MEN1 3603/4885HBB 4836/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | KMT2A 1324/4885MEN1 2508/4885HBB 4552/4885 |
| US-20140213600-A1 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES | PMP22, DPM1, SUCLG1 | KMT2A 1711/4885MEN1 632/4885HBB 2084/4885 |
| US-10471064-B2 | Medicament for treating peripheral neuropathies | NGF, TSLP, BDNF | KMT2A 920/4885MEN1 4356/4885HBB 4273/4885 |
| US-20200046715-A1 | Medicament for Treating Peripheral Neuropathies | NGF, PMP22, BPGM | KMT2A 1810/4885MEN1 3466/4885HBB 2477/4885 |
| US-20180193348-A1 | Medicament for Treating Peripheral Neuropathies | NGF, TSLP, BDNF | KMT2A 920/4885MEN1 4356/4885HBB 4273/4885 |
| US-20170056408-A1 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES | PMP22, SNCA, PARL | KMT2A 1917/4885MEN1 1309/4885HBB 1450/4885 |
| US-20150238493-A1 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES | PMP22, SNCA, PARL | KMT2A 1917/4885MEN1 1309/4885HBB 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.